Literature DB >> 25511666

Bone density in children with single ventricle physiology.

Edgard A Bendaly1, Linda A DiMeglio, William F Fadel, Roger A Hurwitz.   

Abstract

Children with chronic diseases are at risk for low bone mineral density (BMD). There are no studies of BMD in children with congenital heart disease and particularly single ventricle (SV). Children with this defect are often treated with warfarin, suspected to negatively impact BMD in adults. We assessed BMD in patients with SV physiology and compared the BMD of subjects taking warfarin to those who were not. Subjects 5-12 years with SV were included. BMD z scores by dual-energy X-ray absorptiometry of the spine and total body less head (TBLH) were obtained. Calcium intake, activity level, height, and Tanner stage were assessed. Linear regression models and t tests were used to investigate differences between participants and normative data as well as between subjects' subgroups. Twenty-six subjects were included and 16 took warfarin. Mean BMD z score at the spine was significantly lower than expected at -1.0 ± 0.2 (p < 0.0001), as was the BMD z score for TBLH at -0.8 ± 0.2 (p < 0.0001). Those results remained significant after adjusting for height. Subjects who were on warfarin tended to have lower BMD at both the spine and TBLH than those who were not, with a z score difference of 0.6 ± 0.46 at the spine (p = 0.106) and a difference of 0.4 ± 0.34 at TBLH (p = 0.132). BMD is significantly reduced in children with SV. Warfarin appears to lower BMD but the effect is less conclusive. Continued evaluation is recommended for these patients at risk for reduced bone density. Evaluation of other cardiac patients on warfarin therapy should also be considered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25511666      PMCID: PMC4858165          DOI: 10.1007/s00246-014-1083-3

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  39 in total

1.  Changes in bone density after exposure to oral anticoagulants: a meta-analysis.

Authors:  P J Caraballo; S E Gabriel; M R Castro; E J Atkinson; L J Melton
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Clinical report—bone densitometry in children and adolescents.

Authors:  Laura K Bachrach; Irene N Sills
Journal:  Pediatrics       Date:  2010-12-27       Impact factor: 7.124

3.  Clinical spectrum of venous thrombi in the Fontan patient.

Authors:  S E Fletcher; C L Case; D A Fyfe; P C Gillette
Journal:  Am J Cardiol       Date:  1991-12-15       Impact factor: 2.778

4.  The association between bone mineral density, metacarpal morphometry, and upper limb fractures in children: a population-based case-control study.

Authors:  Deqiong Ma; Graeme Jones
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

5.  Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients.

Authors:  W Streif; M Andrew; V Marzinotto; P Massicotte; A K Chan; J A Julian; L Mitchell
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

6.  A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.

Authors:  Paul Monagle; Andrew Cochrane; Robin Roberts; Cedric Manlhiot; Robert Weintraub; Barbara Szechtman; Marina Hughes; Maureen Andrew; Brian W McCrindle
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

7.  Thromboembolism after the Fontan procedure and its modifications.

Authors:  M Jahangiri; D B Ross; A N Redington; C Lincoln; E A Shinebourne
Journal:  Ann Thorac Surg       Date:  1994-11       Impact factor: 4.330

8.  Cerebrovascular accidents following the Fontan operation.

Authors:  A J du Plessis; A C Chang; D L Wessel; J E Lock; G Wernovsky; J W Newburger; J E Mayer
Journal:  Pediatr Neurol       Date:  1995-04       Impact factor: 3.372

9.  Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand.

Authors:  Yves d'Udekem; Ajay J Iyengar; John C Galati; Victoria Forsdick; Robert G Weintraub; Gavin R Wheaton; Andrew Bullock; Robert N Justo; Leeanne E Grigg; Gary F Sholler; Sarah Hope; Dorothy J Radford; Thomas L Gentles; David S Celermajer; David S Winlaw
Journal:  Circulation       Date:  2014-09-09       Impact factor: 29.690

10.  Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders.

Authors:  A H Cromme-Dijkhuis; J Hess; K Hählen; C M Henkens; M T Bink-Boelkens; A A Eygelaar; E Bos
Journal:  J Thorac Cardiovasc Surg       Date:  1993-12       Impact factor: 5.209

View more
  4 in total

1.  An evidence-based perspective on warfarin and the growing skeleton.

Authors:  T Sugiyama; Y Kono; K Sekiguchi; Y T Kim; H Oda
Journal:  Osteoporos Int       Date:  2016-04-18       Impact factor: 4.507

2.  Timing of low bone mineral density and predictors of bone mineral density trajectory in children on long-term warfarin: a longitudinal study.

Authors:  M L Avila; E Pullenayegum; S Williams; A Shammas; J Stimec; E Sochett; K Marr; L R Brandão
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

Review 3.  Nutritional Management of Patients with Fontan Circulation: A Potential for Improved Outcomes from Birth to Adulthood.

Authors:  Letizia Baldini; Katia Librandi; Chiara D'Eusebio; Antonella Lezo
Journal:  Nutrients       Date:  2022-09-29       Impact factor: 6.706

4.  Proceedings From the 2019 Stanford Single Ventricle Scientific Summit: Advancing Science for Single Ventricle Patients: From Discovery to Clinical Applications.

Authors:  Sushma Reddy; Stephanie Siehr Handler; Sean Wu; Marlene Rabinovitch; Gail Wright
Journal:  J Am Heart Assoc       Date:  2020-03-19       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.